Precision therapy for HER2-positive breast cancer / 中华内分泌外科杂志
Chinese Journal of Endocrine Surgery
; (6): 138-142, 2023.
Article
en Zh
| WPRIM
| ID: wpr-989913
Biblioteca responsable:
WPRO
ABSTRACT
Human epidermal growth factor receptor 2 (HER2) -positive breast cancer is prone to metastasis and has a poor prognosis. In the context of the booming development of anti-HER2 targeted therapy, HER2-positive breast cancer has reduced recurrence and metastasis and improved prognosis. However, there are still some HER2-positive breast cancer patients who cannot benefit from anti-HER2-targeted therapy and continue to develop recurrent metastasis. Neoadjuvant therapy, surgical treatment, and the full range of adjuvant and palliative therapies enable HER2-positive breast cancer to benefit from them. Scholars from home and abroad have explored the treatment of HER2-positive breast cancer and have achieved some results. In this article, we review the current status and development of HER2-positive breast cancer treatment.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Endocrine Surgery
Año:
2023
Tipo del documento:
Article